[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Moral‐Sanz et al., 2022 - Google Patents

The structural conformation of the tachykinin domain drives the anti‐tumoural activity of an octopus peptide in melanoma BRAFV600E

Moral‐Sanz et al., 2022

View PDF @Full View
Document ID
1657717805134078640
Author
Moral‐Sanz J
Fernandez‐Rojo M
Colmenarejo G
Kurdyukov S
Brust A
Ragnarsson L
Andersson
Vila S
Cabezas‐Sainz P
Wilhelm P
Vela‐Sebastián A
Fernández‐Carrasco I
Chin Y
López‐Mancheño Y
Smallwood T
Clark R
Fry B
King G
Ramm G
Alewood P
Lewis R
Mulvenna J
Boyle G
Sanchez L
Neely G
Miles J
Ikonomopoulou M
Publication year
Publication venue
British Journal of Pharmacology

External Links

Snippet

Background and Purpose Over past decades, targeted therapies and immunotherapy have improved survival and reduced the morbidity of patients with BRAF‐mutated melanoma. However, drug resistance and relapse hinder overall success. Therefore, there is an urgent …
Continue reading at bpspubs.onlinelibrary.wiley.com (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

Similar Documents

Publication Publication Date Title
Millard et al. Targeting class I histone deacetylases in a “complex” environment
Piganis et al. Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) signaling via the interferon α receptor (IFNAR1)-associated tyrosine kinase Tyk2
Dietrich et al. Cell permeable stapled peptide inhibitor of Wnt signaling that targets β-catenin protein-protein interactions
Ikonomopoulou et al. Gomesin inhibits melanoma growth by manipulating key signaling cascades that control cell death and proliferation
Assimon et al. Specific binding of tetratricopeptide repeat proteins to heat shock protein 70 (Hsp70) and heat shock protein 90 (Hsp90) is regulated by affinity and phosphorylation
Lopez et al. CARD-mediated autoinhibition of cIAP1's E3 ligase activity suppresses cell proliferation and migration
Clague et al. Deubiquitylases from genes to organism
Cheloha et al. PTH receptor-1 signalling—mechanistic insights and therapeutic prospects
Bruey et al. Bcl-2 and Bcl-XL regulate proinflammatory caspase-1 activation by interaction with NALP1
Meinander et al. Ubiquitylation of the initiator caspase DREDD is required for innate immune signalling
Ng et al. Amplification of Drosophila olfactory responses by a DEG/ENaC channel
Ma et al. Proteasome-independent polyubiquitin linkage regulates synapse scaffolding, efficacy, and plasticity
West et al. Small molecule activators of the heat shock response: chemical properties, molecular targets, and therapeutic promise
Bowers et al. Sulfiredoxin redox-sensitive interaction with S100A4 and non-muscle myosin IIA regulates cancer cell motility
JP2011504461A (en) Methods and compositions for measuring WNT activity and for treating WNT-related cancers
Glogowska et al. C1q‐tumour necrosis factor‐related protein 8 (CTRP8) is a novel interaction partner of relaxin receptor RXFP1 in human brain cancer cells
Li et al. Neuropeptide VGF C-terminal peptide TLQP-62 alleviates lipopolysaccharide-induced memory deficits and anxiety-like and depression-like behaviors in mice: the role of BDNF/TrkB signaling
Ahmed et al. Loss of correlations among proteins in brains of the Ts65Dn mouse model of down syndrome
Anchoori et al. Covalent Rpn13-binding inhibitors for the treatment of ovarian cancer
Mohanraj et al. Mitochondrial control of cellular protein homeostasis
D’Acunzo et al. Reversible induction of mitophagy by an optogenetic bimodular system
Latorre et al. Mice expressing fluorescent PAR2 reveal that endocytosis mediates colonic inflammation and pain
Kasinath et al. Recent structural insights into polycomb repressive complex 2 regulation and substrate binding
Tundo et al. Multiple allosteric sites are involved in the modulation of insulin‐degrading‐enzyme activity by somatostatin
Yang et al. Optimization of beclin 1-targeting stapled peptides by staple scanning leads to enhanced antiproliferative potency in cancer cells